[HTML][HTML] Correlates of vaccine-induced protection against SARS-CoV-2
T Koch, SC Mellinghoff, P Shamsrizi, MM Addo… - Vaccines, 2021 - mdpi.com
We are in the midst of a pandemic caused by the novel severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS…
coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). SARS…
[HTML][HTML] Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
T Koch, C Dahlke, A Fathi, A Kupke… - The Lancet Infectious …, 2020 - thelancet.com
Background The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public …
[PDF][PDF] Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
…, A Fathi, MP Raadsen, AZ Mykytyn, T Koch… - Cell Reports …, 2022 - cell.com
The Middle East respiratory syndrome (MERS) is a respiratory disease caused by MERS
coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of …
coronavirus (MERS-CoV). In follow up to a phase 1 trial, we perform a longitudinal analysis of …
The COVID-19 vaccine landscape
T Koch, A Fathi, MM Addo - Coronavirus Disease-COVID-19, 2021 - Springer
The history of vaccine development spans centuries. At first, whole pathogens were used as
vaccine agents, either inactivated or attenuated, to reduce virulence in humans. Safety and …
vaccine agents, either inactivated or attenuated, to reduce virulence in humans. Safety and …
Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
C Dahlke, J Heidepriem, R Kobbe, R Santer, T Koch… - MedRxiv, 2020 - medrxiv.org
SARS-CoV-2 is the causative agent of COVID-19 and is a severe threat to global health.
Patients infected with SARS-CoV-2 show a wide range of symptoms and disease severity, while …
Patients infected with SARS-CoV-2 show a wide range of symptoms and disease severity, while …
[HTML][HTML] Longitudinal development of antibody responses in COVID-19 patients of different severity with ELISA, peptide, and glycan arrays: an immunological case …
J Heidepriem, C Dahlke, R Kobbe, R Santer, T Koch… - Pathogens, 2021 - mdpi.com
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for …
coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for …
[HTML][HTML] Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
…, G Paris, S Lassen, M Klüver, A Volz, T Koch… - Nature …, 2022 - nature.com
Vaccine development is essential for pandemic preparedness. We previously conducted a
Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East …
Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East …
[HTML][HTML] Focussed Assessment with Sonography in acute Lassa Fever (FASLa): Development of a point-of-care protocol and description of common ultrasound …
CO Erameh, T Koch, OI Edeawe, L Oestereich… - Journal of Infection, 2023 - Elsevier
Background Managing Lassa fever (LF) patients is challenging because of the complexity of
this life-threatening infectious disease, the necessary isolation measures, and the limited …
this life-threatening infectious disease, the necessary isolation measures, and the limited …
Pharmacokinetics of ribavirin in the treatment of Lassa fever: an observational clinical study at the Irrua specialist teaching hospital, Edo State, Nigeria
…, A Thielebein, L Aihonwalan, T Koch… - Clinical Infectious …, 2023 - academic.oup.com
Background Lassa fever is endemic in large parts of West Africa. The recommended antiviral
treatment is ribavirin. Two treatment regimens are currently endorsed in Nigeria: the “…
treatment is ribavirin. Two treatment regimens are currently endorsed in Nigeria: the “…
[HTML][HTML] Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins
T Koch, M Rottstegge, P Ruibal, S Gomez-Medina… - Viruses, 2020 - mdpi.com
The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in
equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in …
equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in …
